<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02048917</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-13-MULTI-13-KCTN-1301</org_study_id>
    <secondary_id>KCTN-1301</secondary_id>
    <nct_id>NCT02048917</nct_id>
  </id_info>
  <brief_title>Optimization of Smoking Cessation Strategies Concurrent With Treatment of Tobacco Related Malignancies</brief_title>
  <official_title>Optimization of Smoking Cessation Strategies Concurrent With Treatment of Tobacco Related Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kentucky</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kentucky Lung Cancer Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find an optimal smoking cessation strategy in patients
      undergoing therapy for lung and head and neck cancers at selected cancer centers in Kentucky
      by delivering high quality smoking cessation to all enrolled patients. This study will also
      examine the feasibility of routinely implementing an array of smoking cessation strategies
      for this patient population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects enrolled in the study will be placed in one of twelve treatment arms. Subjects in
      each of the twelve treatment regimens will receive either varenicline or bupropion or
      long-acting nicotine replacement therapy, with or without use of supplemental nicotine
      replacement therapy, and in combination with either standard of care smoking cessation
      counseling or high intensity/motivational smoking cessation counseling.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 22, 2014</start_date>
  <completion_date type="Actual">May 15, 2019</completion_date>
  <primary_completion_date type="Actual">May 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cigarette use</measure>
    <time_frame>8 weeks</time_frame>
    <description>Seven day point prevalence of cigarette use confirmed with CO testing at eight weeks.</description>
  </primary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>High Intensity Counseling + Long Acting NRT + PRN NRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Intensity Counseling + Long Acting NRT + PRN NRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Intensity Counseling + bupropion + PRN NRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Intensity Counseling + bupropion + PRN NRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Intensity Counseling + varenicline + PRN NRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Intensity Counseling + varenicline + PRN NRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Intensity Counseling + Long Acting NRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Intensity Counseling + Long Acting NRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Intensity Counseling + bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Intensity Counseling + bupropion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Intensity Counseling + varenicline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Intensity Counseling + varenicline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Intensity Counseling + Long Acting NRT + PRN NRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Intensity Counseling + Long Acting NRT + PRN NRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Intensity Counseling + bupropion + PRN NRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Intensity Counseling + bupropion + PRN NRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Intensity Counseling + varenicline + PRN NRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Intensity Counseling + varenicline + PRN NRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Intensity Counseling + Long Acting NRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Intensity Counseling + Long Acting NRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Intensity Counseling + bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Intensity Counseling + bupropion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Intensity Counseling + varenicline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Intensity Counseling + varenicline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Intensity Counseling + Long Acting NRT + PRN NRT</intervention_name>
    <description>High Intensity Counseling + Long Acting NRT + PRN NRT</description>
    <arm_group_label>High Intensity Counseling + Long Acting NRT + PRN NRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Intensity Counseling + bupropion + PRN NRT</intervention_name>
    <description>High Intensity Counseling + bupropion + PRN NRT</description>
    <arm_group_label>High Intensity Counseling + bupropion + PRN NRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Intensity Counseling + varenicline + PRN NRT</intervention_name>
    <description>High Intensity Counseling + varenicline + PRN NRT</description>
    <arm_group_label>High Intensity Counseling + varenicline + PRN NRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Intensity Counseling + Long Acting NRT</intervention_name>
    <description>High Intensity Counseling + Long Acting NRT</description>
    <arm_group_label>High Intensity Counseling + Long Acting NRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Intensity Counseling + bupropion</intervention_name>
    <description>High Intensity Counseling + bupropion</description>
    <arm_group_label>High Intensity Counseling + bupropion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Intensity Counseling + varenicline</intervention_name>
    <description>High Intensity Counseling + varenicline</description>
    <arm_group_label>High Intensity Counseling + varenicline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Intensity Counseling + Long Acting NRT + PRN NRT</intervention_name>
    <description>Low Intensity Counseling + Long Acting NRT + PRN NRT</description>
    <arm_group_label>Low Intensity Counseling + Long Acting NRT + PRN NRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Intensity Counseling + bupropion + PRN NRT</intervention_name>
    <description>Low Intensity Counseling + bupropion + PRN NRT</description>
    <arm_group_label>Low Intensity Counseling + bupropion + PRN NRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Intensity Counseling + varenicline + PRN NRT</intervention_name>
    <description>Low Intensity Counseling + varenicline + PRN NRT</description>
    <arm_group_label>Low Intensity Counseling + varenicline + PRN NRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Intensity Counseling + Long Acting NRT</intervention_name>
    <description>Low Intensity Counseling + Long Acting NRT</description>
    <arm_group_label>Low Intensity Counseling + Long Acting NRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Intensity Counseling + bupropion</intervention_name>
    <description>Low Intensity Counseling + bupropion</description>
    <arm_group_label>Low Intensity Counseling + bupropion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Intensity Counseling + varenicline</intervention_name>
    <description>Low Intensity Counseling + varenicline</description>
    <arm_group_label>Low Intensity Counseling + varenicline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be ≥ 18 years of age.

          -  Patient with newly diagnosed or recurrent, histologic diagnosis of any of the
             following tobacco related malignancies:

               1. Lung or Bronchus cancer or Head &amp; Neck, cancers (all sites).

               2. Esophagus, Stomach, Pancreas, Kidney, Urinary Bladder, Colon, Rectum, Cervix,
                  Vulvar, Vaginal

               3. Carcinoma in situ undergoing definitive surgical resection or treatment (ex:
                  radiation of the larynx, and gynecologic tract hysterectomy, vulvectomy - except
                  gynecologic patients undergoing ablative or local excisional therapies [laser
                  ablation,cervical conization, LEEP].

          -  Having smoked at least 1 cigarette within 4 weeks of study enrollment.

          -  Having at least a 10-pack year history of cigarette smoking.

          -  Having smoked at least one cigarette within 1 month of cancer diagnosis.

          -  Life expectancy is greater than 1 year.

          -  Patient has an AUDIT score of &lt; 10.

          -  Patient has ECOG Performance Status of &lt;=2.

          -  Patients must have the ability to understand and the willingness to provide signed
             written informed consent document.

        Exclusion Criteria:

          -  Known allergy attributed to bupropion, varenicline, transdermal or lozenge nicotine.

          -  History of suicide attempt or preparation for attempt within the past 10 years.

          -  C-SRSS Baseline/Screening:

               1. Patient response of &quot;Yes&quot; to any question except question 1.

               2. Patient response of &quot;Yes&quot; to any question in column one (lifetime), except
                  question 1, is not exclusionary unless judged by the investigator to be
                  significant in ideation, intensity, behavior or attempts, and precludes
                  participation.

          -  Hospitalized for psychiatric illness within the past two years.

          -  History of Bipolar disorder.

          -  Currently taking Bupropion for depression.

          -  Patient has taken monoamine oxidase inhibitors (MAOI) in the past two weeks.

          -  History of eating disorder such as anorexia or bulimia.

          -  Active widespread skin disorders such as psoriasis, chronic urticarial or dermatitis

          -  History of epilepsy or seizure disorder.

          -  Active severe kidney or liver disease.

          -  Women must not be pregnant or lactating. Women of reproductive-potential must have
             negative serum or urine pregnancy test within 7 days prior to study enrollment and
             agree to use method of contraception during and for 30 days following last cessation
             drug dose.

          -  Patients within three months of a myocardial infarction.

          -  Patients with unstable angina or serious arrhythmia.

          -  Patients with psychiatric disability judged by the investigator to be clinically
             significant so as to preclude informed consent or compliance with drug intake.

          -  Patient taking varenicline or bupropion within one month of study enrollment.

          -  Participation in any other investigational drug study within 4 weeks of study
             enrollment.

          -  Currently enrolled in other professional tobacco cessation therapeutic intervention.

          -  Enrollment in a concurrent cancer therapeutic trial will require prior review and
             approval by the study site PI to determine that there are no drug interactions
             concerns.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Valentino, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King's Daughters Medical Center</name>
      <address>
        <city>Ashland</city>
        <state>Kentucky</state>
        <zip>41101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hardin Memorial Health Cancer Care Center</name>
      <address>
        <city>Elizabethtown</city>
        <state>Kentucky</state>
        <zip>42701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARH Cancer Center</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Cancer Clinic</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lexington Veterans Affair Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Kentucky, Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville, James Graham Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Claire Regional Medical Center</name>
      <address>
        <city>Morehead</city>
        <state>Kentucky</state>
        <zip>40351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Owensboro Health</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Medical Center</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 27, 2014</study_first_submitted>
  <study_first_submitted_qc>January 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2014</study_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Joseph Valentino</investigator_full_name>
    <investigator_title>Study Chair</investigator_title>
  </responsible_party>
  <keyword>Smoking</keyword>
  <keyword>Cessation</keyword>
  <keyword>Bupropion</keyword>
  <keyword>Varenicline</keyword>
  <keyword>Nicotine</keyword>
  <keyword>Counseling</keyword>
  <keyword>Tobacco</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

